A Phase I/II Clinical Trial of Topical KB105, a Replication-incompetent, Non-integrating HSV-1 Vector Expressing Human Transglutaminase 1 (TGM1) for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)
Phase of Trial: Phase I/II
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs KB105 (Primary)
- Indications Ichthyosis
- Focus Adverse reactions; First in man
- Acronyms GEM-3
- Sponsors Krystal Biotech
- 10 Oct 2019 According to a Krystal Biotech media release, the interim results (n=2) from this study is expected in 1H 2020.
- 04 Sep 2019 According to a Krystal Biotech media release, pediatric patients will be enrolled in the study following establishment of safety in adult subjects.
- 26 Aug 2019 Status changed from not yet recruiting to recruiting.